三碘甲状腺原氨酸治疗对射血分数保留的心力衰竭动物模型的影响
在ZSF1肥胖大鼠代谢诱导的射血分数保留的心力衰竭(HFpEF)模型中,从第13周至第24周经饮水给予低剂量或替代剂量三碘甲状腺原氨酸(T3)。T3治疗改善代谢谱、心肌钙处理及心脏功能,但替代剂量组出现心率增快、室性早搏增多及3例死亡。
要点
- HFpEF动物血清及心肌甲状腺激素水平低于ZSF1 Lean对照组。
- 替代剂量T3使心肌T3水平恢复正常,低剂量未使血清T3正常化。
- 替代剂量T3与心率增快、室性早搏增多及3例死亡相关,低剂量耐受性良好。
核心结论
- T3治疗可改善代谢谱、心肌钙处理和心脏功能;低剂量耐受性良好且安全,替代剂量与心率增快、心律失常风险增加及猝死相关。
- 甲状腺激素调节可能是HFpEF的潜在治疗靶点,但需考虑T3在此状况下的窄治疗窗。
研究设计与样本
- 动物模型研究,评估四组ZSF1大鼠:ZSF1 Lean对照组(n=8)、ZSF1肥胖HFpEF组(n=13)、ZSF1肥胖替代剂量T3组(n=8)和ZSF1肥胖低剂量T3组(n=8)。
- T3经饮水给药,从第13周至第24周;第22周进行人体测量、代谢评估、超声心动图和峰值运动测试(测定最大氧耗量VO2max),第24周进行终末血流动力学评估,随后采集心肌样本进行单心肌细胞评估和分子研究。
主要发现
- HFpEF动物血清和心肌甲状腺激素水平低于Lean-Ctrl组。
- T3治疗未使血清T3水平正常化,但HFpEF-T3high组心肌T3水平升至正常。
- 与HFpEF组相比,两个T3治疗组体重均显著降低;葡萄糖代谢改善仅见于HFpEF-T3high组。
- 两个治疗组在体内均改善舒张和收缩功能,在体外均改善Ca2+瞬变、肌节缩短和松弛。
- 与HFpEF动物相比,HFpEF-T3high组心率增加且室性早搏发生率更高;T3治疗组心肌RYR2和α-MHC表达升高、β-MHC表达降低;VO2max未受T3治疗影响;两个治疗组心肌纤维化均减少;HFpEF-T3high组有3只动物死亡。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Low levels of triiodothyronine (T3) are common in patients with heart failure (HF). Our aim was to evaluate the effects of supplementation with low and replacement doses of T3 in an animal model of HF with preserved ejection fraction (HFpEF). Methods: We evaluated four groups: ZSF1 Lean (n = 8, Lean-Ctrl), ZSF1 Obese (rat model of metabolic-induced HFpEF, n = 13, HFpEF), ZSF1 Obese treated with a replacement dose of T3 (n = 8, HFpEF-T3high), and ZSF1 Obese treated with a low-dose of T3 (n = 8, HFpEF-T3low). T3 was administered in drinking water from weeks 13 to 24. The animals underwent anthropometric and metabolic assessments, echocardiography, and peak effort testing with maximum O2 consumption (VO2max) determination at 22 weeks, and a terminal hemodynamic evaluation at 24 weeks. Afterwhile myocardial samples were collected for single cardiomyocyte evaluation and molecular studies. Results: HFpEF animals showed lower serum and myocardial thyroid hormone levels than Lean-Ctrl. Treatment with T3 did not normalize serum T3 levels, but increased myocardial T3 levels to normal levels in the HFpEF-T3high group. Body weight was significantly decreased in both the T3-treated groups, comparing with HFpEF. An improvement in glucose metabolism was observed only in HFpEF-T3high. Both the treated groups had improved diastolic and systolic function in vivo, as well as improved Ca2+ transients and sarcomere shortening and relaxation in vitro. Comparing with HFpEF animals, HFpEF-T3high had increased heart rate and a higher rate of premature ventricular contractions. Animals treated with T3 had higher myocardial expression of calcium transporter ryanodine receptor 2 (RYR2) and α-myosin heavy chain (MHC), with a lower expression of β-MHC. VO2max was not influenced by treatment with T3. Myocardial fibrosis was reduced in both the treated groups. Three animals died in the HFpEF-T3high group. Conclusions: Treatment with T3 was shown to improve metabolic profile, myocardial calcium handling, and cardiac function. While the low dose was well-tolerated and safe, the replacement dose was associated with increased heart rate, and increased risk of arrhythmias and sudden death. Modulation of thyroid hormones may be a potential therapeutic target in HFpEF; however, it is important to take into account the narrow therapeutic window of T3 in this condition.
引用
- Neves JS, Leite AR, Conceição G, et al. Effects of Triiodothyronine Treatment in an Animal Model of Heart Failure with Preserved Ejection Fraction. Thyroid. 2023. PMID: 37140469. doi:10.1089/thy.2022.0717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。